Orion Oyj (ORINF)
| Previous close | 43.02 |
| Open | 47.16 |
| Bid | 49.92 x 40000 |
| Ask | 54.92 x 41800 |
| Day's range | 47.16 - 47.16 |
| 52-week range | 37.00 - 47.16 |
| Volume | |
| Avg. volume | 0 |
| Market cap | 6.063B |
| Beta (5Y monthly) | 0.35 |
| PE ratio (TTM) | 28.02 |
| EPS (TTM) | 1.37 |
| Earnings date | 29 Oct 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | 15 Oct 2024 |
| 1y target est | N/A |
- GlobeNewswire
Darolutamide plus androgen deprivation therapy significantly reduced the risk of radiological progression or death by 46% compared to placebo plus ADT in patients with metastatic hormone-sensitive prostate cancer
ORION CORPORATION PRESS RELEASE 16 SEPTEMBER 2024 at 11.30 EEST Darolutamide plus androgen deprivation therapy significantly reduced the risk of radiological progression or death by 46% compared to placebo plus ADT in patients with metastatic hormone-sensitive prostate cancer Results from the pivotal Phase III ARANOTE trial evaluating darolutamide plus androgen deprivation therapy (ADT) showed a statistically significant increase in radiological progression-free survival (rPFS) compared to place
- GlobeNewswire
Inside information: Orion upgrades full-year outlook for 2024
ORION CORPORATION STOCK EXCHANGE RELEASE – INSIDE INFORMATION11 SEPTEMBER 2024 at 09:30 EEST Inside information: Orion upgrades full-year outlook for 2024 Orion Corporation upgrades the full-year outlook for 2024 both for the part regarding net sales and operating profit. Orion’s product sales and royalty income has continued to grow faster than expected during the second half of 2024 and this good development is anticipated to continue during the remainder of the year. Due to these reasons, Ori
Zacks3 Reasons Why Growth Investors Shouldn't Overlook Orion OYJ (ORINY)
Orion OYJ (ORINY) is well positioned to outperform the market, as it exhibits above-average growth in financials.
